Flibanserin
is a long-chain arylpiperazine with an interesting story behind it. The
molecule is classified as a 5-HT1A agonist and 5-HT2A antagonist, and had
initially been developed as an antidepressant. Later it was found that it
exerts potential antipsychotic effects. A molecule with multiple indication is good news but "very
good news" was still hiding.
All the heavens must have rejoiced when Flibanserin was shortlisted by Boehringer Ingelheim as a drug to boost women sexual desire. Maybe not the Heavens, but surly the CEOs must have. Converting a pill into Bentley via FDA-catalyzed process is all CEOs dream-come-true........
Flibanserin
is being studied as a non-hormonal treatment for pre-menopausal women with
hypoactive sexual desire disorder (HSDD). In simple words, the pill will a mood
changer for the females, which if you ask any female is not true.
The
operating systems (OS) for males and females have very different coding. Males
are usually uni-directional beings, as compared to females which are
multi-tasking. Male when goes to buy a pair of shoe, he buys a pair of shoe,
but a female.... hmmm, we all know the story. So, for such a complex framework,
finding any solution is not easy. Maybe the people at FDA thought same, so they
gave negative report to Flibanserin, when Boehringer Ingelheim approached them
in year 2010.
Heartbroken
but able-minded, Boehringer Ingelheim transferred Flibanserin to Sprout
Pharmaceuticals which is continuing the drug development process. Now, they
have submitted a new report to FDA, with extra information that FDA have asked
for.
The
entire internet is going GA-GA over this new development, as if we all will get
shiny Bentley’s. What we fail to understand is that here is that just few words of respect/love might do the magic for
her, what an antidepressant/ antipsychotic/mood-changer hopes to do.
Sprout Pharmaceuticals achieved approval of the drug by the US FDA in August 2015.
Sprout Pharmaceuticals achieved approval of the drug by the US FDA in August 2015.
